Drug Database · Clinicians

Dobutamine

Brands (54) Dobexon, Dobucard, Dobumax…Show all

Adrenergic and dopaminergic agent; Adrenergic agent; and others PH FDA category

Rx · Prescription drug61 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 89becb0c-da60-4f43-0a98-29ff7a9eca58, version date May 27, 2026 (DOBUTAMINE · Hospira, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Dobutamine Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility…
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Dobutamine Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine hydrochloride.

Contraindications

CONTRAINDICATIONS Dobutamine hydrochloride is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to Dobutamine Injection, USP solution.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Note − Do not add Dobutamine Injection, USP to 5% Sodium Bicarbonate Injection or to any other strongly alkaline solution. Because of potential physical incompatibilities, it is recommended that dobutamine hydrochloride not be mixed with other drugs in the same solution. Dobutamine hydrochloride should not be used in conjunction with other agents or diluents containing both sodium bisulfite and ethanol.

Preparation and Stability − At the time of administration, Dobutamine Injection, USP must be further diluted in an intravenous container to at least a 50 mL solution using one of the following intravenous solutions as a diluent: 5% Dextrose Injection, USP; 5% Dextrose and 0.45% Sodium Chloride Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; 10% Dextrose Injection, USP; Isolyte ® M with 5% Dextrose Injection; Lactated Ringer's Injection; 5% Dextrose in Lactated Ringer's Injection; Normosol ® -M in D5-W; 20% Osmitrol ® in Water for Injection; 0.9% Sodium Chloride Injection, USP; or Sodium Lactate Injection, USP. Intravenous solutions should be used within 24 hours.

Recommended Dosage − The rate of infusion needed to increase cardiac output usually ranged from 2.5 to 15 mcg/kg/min (see Table 1). On rare occasions, infusion rates up to 40 mcg/kg/min have been required to obtain the desired effect. Table 1 Dobutamine Infusion Rate (mL/kg/min) for Concentrations of 250, 500, and 1,000 mcg/mL Infusion Delivery Rate Drug Delivery Rate 250 mcg/mL 250 mcg/mL of diluent 500 mcg/mL 500 mcg/mL or 250 mg/500 mL of diluent 1,000 mcg/mL 1,000 mcg/mL or 250 mg/250 mL of diluent (mcg/kg/min) (mL/kg/min) (mL/kg/min) (mL/kg/min) 2.5 0.01 0.005 0.0025 5 0.02 0.01 0.005 7.5 0.03 0.015 0.0075 10 0.04 0.02 0.01 12.5 0.05 0.025 0.0125 15 0.06 0.03 0.015 Rates of infusion in mL/h for Dobutamine concentrations of 500 mcg/mL, 1,000 mcg/mL, and 2,000 mcg/mL are given in Table 2.

Table 2 Dobutamine Infusion Rate (mL/h) for 500 mcg/mL concentration Drug Delivery Rate (mcg/kg/min) Patient Body Weight (kg) 30 40 50 60 70 80 90 100 110 2.5 9 12 15 18 21 24 27 30 33 5 18 24 30 36 42 48 54 60 66 7.5 27 36 45 54 63 72 81 90 99 10 36 48 60 72 84 96 108 120 132 12.5 45 60 75 90 105 120 135 150 165 15 54 72 90 108 126 144 162 180 198 Dobutamine Infusion Rate (mL/h) for 1,000 mcg/mL concentration Drug Delivery Rate (mcg/kg/min) Patient Body Weight (kg) 30 40 50 60 70 80 90 100 110 2.5 4.5 6 7.5 9 10.5 12 13.5 15 16.5 5 9 12 15 18 21 24 27 30 33 7.5 13.5 18 22.5 27 31.5 36 40.5 45 49.5 10 18 24 30 36 42 48 54 60 66 12.5 22.5 30 37.5 45 52.5 60 67.5 75 82.5 15 27 36 45 54 63 72 81 90 99 Dobutamine Infusion Rate (mL/h) for 2000 mcg/mL concentration Drug Delivery Rate (mcg/kg/min) Patient Body Weight (kg) 30 40 50 60 70 80 90 100 110 2.5 2 3 4 4.5 5 6 7 7.5 8 5 4.5 6 7.5 9 10.5 12 13.5 15 16.5 7.5 7 9 11 13.5 16 18 20 22.5 25 10 9 12 15 18 21 24 27 30 33 12.5 11 15 19 22.5 26 30 34 37.5 41 15 13.5 18 22.5 27 31.5 36 40.5 45 49.5 The rate of administration and the duration of therapy should be adjusted according to the patient's response as determined by heart rate, presence of ectopic activity, blood pressure, urine flow, and, whenever possible, measurement of central venous or pulmonary wedge pressure and cardiac output. Concentrations of up to 5,000 mcg/mL have been administered to humans (250 mg/50 mL).

The final volume administered should be determined by the fluid requirements of the patient. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use – The safety and effectiveness of Dobutamine Injection, USP for use in pediatric patients have not been studied.

Dosage forms

Philippines

  • ) solution for injection: 12.5 mg/mL (250 mg/20 mL, 12.50 mg/mL (250 mg/20 mL, 12.50 mg/mL(250 mg/20 mL, 25 mg/mL (250 mg/10 mL, 50 mg/mL (250 mg/5 mL
  • Solution for injection: 12.5 mg/mL, 50 mg/mL
  • Solution for intravenous infusion: 50 mg/mL
  • ) solution for iv infusion: 12.5 mg/mL (250 mg/20 mL, 50 mg/mL (250 mg/5 mL
  • Solution for iv infusion: 50 mg/mL
  • ) solution for injection for i.v. infusion: 12.5 mg/mL (250 mg/20 mL, 50 mg/mL (250 mg/5 mL
  • ) solution for i.v. injection: 50 mg/mL (250 mg/5 mL, 50 mg/mL (250 mg/mL
  • Solution for i.v. infusion: 50 mg/mL
  • ) concentrate solution for infusion: 50 mg/mL (250 mg/5 mL
  • ) solution for iv injection: 50 mg/mL (250 mg/5 mL

and 4 more forms; see the products table.

Registered products in the Philippines

61 products registered with the Food and Drug Administration (FDA) Philippines list Dobutamine as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Dobutamin (as Hydrochloride) (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products61
Philippine FDA-registered products for Dobutamine
Package insert
Bildobex 50Dobutamine (as Hydrochloride)
50mg/mL Solution for Intravenous (IV) Infusion5mL USP Type I Amber glass Ampoule x 5's in plastic tray (Box of 5's)
Rx
MACKUR LABORATORIES LIMITEDIndia
Afree Pharmaceutical Distribution Corp.
DRP-11918
May 20, 2027
BlissdomineDobutamine (as hydrochloride)
50 mg/mL Solution for Intravenous (I.V. Infusion)5 mL USP Type I Amber Glass Ampoule x 5's in plastic tray (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp.
DRP-11918-01
May 20, 2027
CardinDobutamine (as Hydrochloride)
50 mg/mL (250mg/5mL) Solution for Injection for I.V. InfusionUSP Type I amber coloured glass ampoule x 5 mL (Box of 5's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Despina Pharma Inc.
DRP-13429
Feb 16, 2028
CardiotamineDobutamine (as Hydrochloride)
50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Pharmaessence Inc.Importer: H & B Pharma International Inc.
DRP-5723-07
Jul 18, 2028
CardobDobutamine (as Hydrochloride)
50 mg/mL (250 mg/ 5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Ellebasy Medicale TradingImporter: H & B Pharma International Inc.
DRP-5723
Jul 18, 2028
CentraminDobutamine (as Hydrochloride)
50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Central West Medicale Inc.Importer: H & B Pharma International Inc.
DRP-5723-10
Jul 18, 2028
DELEXARDDobutamine (as hydrochloride)
50 mg/mL (250 mg/5 mL) Solution for I.V. Injection5 mL Type 1 Clear and Colorless Glass Ampoule in PVC Tray Box of 5's
Rx
PT FERRON PAR PHARMACEUTICALSIndonesia
JMN BROTHERS PHARMA LIMITED, INC.Importer: GLORIOUS DEXA MANDAYA, INC.Trader: PT DEXA MEDICA
DRP-8132-01
Apr 28, 2029
DobexonDobutamine (as Hydrochloride)
50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Jackson Pharmaceuticals Inc.Importer: H & B Pharma International Inc.
DRP-5723-14
Jul 18, 2028
DobexonDobutamine (as hydrochloride)
50 mg/mL Solution for Intravenous InfusionUSP Type I Amber glass ampoule x 5 mL in PVC Tray (Box of 5’s)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Jackson Pharmaceuticals Inc.Importer: JLT Pharma Inc.
DRP-9050-04
Aug 26, 2031
DobstalDobutamine (as hydrochloride)
250 mg Lyophilized Powder for Intravenous InfusionUSP Type I Flint Tubular Glass Vial Sealed with 20 mm Grey Bromobutyl Rubber Stopper and Aluminum Flip-off Seal x 20 mL (Box of 1's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Coporation
DRP-8356
Sep 9, 2029
DobubaxDobutamine (as hydrochloride)
12.5 mg/mL (250 mg/20 mL) Solution for Injection (I.M./I.V.)USP Type I Clear Glass Vial x 20 mL (Box of 1's)
Rx
Friends Pharma (Pvt.) Ltd.Pakistan
Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-9089
May 12, 2031
DobucardDobutamine (as Hydrochloride)
12.5 mg/ml (250 mg/20 ml) Solution for injection (I.V.)20 ml USP Type I Amber Glass Vial (Box of 1's)
Rx
Ciron Drugs & Pharmaceuticals Pvt., Ltd.India
PHIL PHARMAWEALTH INC.Trader: Oboi Laboratories
DRP-4094
Nov 20, 2027
DobucardDobutamine (as hydrochloride)
25 mg/mL (250 mg/10 mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule x 10 mL Box of 10's
Rx
Ciron Drugs & Pharmaceuticals Pvt., Ltd.India
Phil Pharmawealth Inc.Trader: Oboi Laboratories
DRP-3176
Oct 5, 2029
DobucoreDobutamine (as Hydrochloride)
50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Greencore Pharma Inc.Importer: H & B Pharma International Inc.
DRP-5723-04
Jul 18, 2028
DobucyDobutamine (as hydrochloride)
50 mg/mL Solution for IV InfusionType I Clear Glass Ampoule x 5 mL (Box of 5's)
Rx
Farbe Firma Pvt. LtdIndia
Cyden Medicale Trading Inc.Importer: AMB HK Enteprises Inc.
DRP-12541-01
Aug 30, 2027
DobufreeDobutamine (as hydrochloride)
50 mg/mL Solution for Intravenous (I.V.) Infusion5 mL USP Type I Amber Glass Ampoule x 5's in plastic tray (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
Bliss Pharma Distribution And Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp.
DRP-11918-02
May 20, 2027
Dobufril-12.5Dobutamine (as hydrochloride)
12.5 mg/mL Solution for Injection (IV)USP Type III Clear glass vial x 20 mL in a plastic tray (Box of 1’s)
Rx
Cooper Pharma LimitedIndia
Bansan Pharma DistributorImporter: Ambica International Corporation
DRP-11964
May 24, 2032
Dobufril-50Dobutamine (As hydrochloride)
50 mg/ mL Solution for Injection (IV)USP Type I amber glass ampoule x 5 mL (Box of 5's)
Rx
Cooper Pharma LimitedIndia
Ambica International Corporation
DRP-11963
May 24, 2027
DobugenDobutamine (as Hydrochloride)
50 mg/mL (250 mg/5 mL) Solution for Injection (IV)USP Type I Glass Ampoule x 5 mL Box of 10's
Rx
Celogen Pharma Pvt. Ltd.India
Pharmastar Int'l Trading Corp.
DR-XY43891
Nov 18, 2029
DobuheartDobutamine (as hydrochloride)
250 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type 1 flint tubular glass vial with grey bromo butyl rubber stopper and sealed with aluminum flip off seal (Box of l’s)
Rx
Indasi Lifesciences Pvt. Ltd.India
Aglobal Care, Inc.
DRP-12274
Jul 8, 2027
DobukonDobutamine (as Hydrochloride)
50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Pharmakon Pharmaceutical Inc.Importer: H & B Pharma International Inc.
DRP-5723-12
Jul 18, 2028
DobulexDobutamine (as hydrochloride)
50 mg/mL (250 mg/5 mL) Concentrate Solution for InfusionClear Glass Ampoule x 5 mL (Box of 5's)
Rx
United Biotech Pvt. LimitedIndia
Delex Pharma International, Inc.
DRP-10473
Nov 2, 2030
DobumakDobutamine (as hydrochloride)
50 mg/mL Solution for Injection (IV)USP Type I Amber glass ampoule x 5 mL (Box of 10's)
Rx
Makcur Laboratories LimitedIndia
Hillcross Prime, Inc.
DRP-11965
May 24, 2027
DobumarcDobutamine (as Hydrochloride)
50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Marcburg Philippines Inc.Importer: H & B Pharma International Inc.
DRP-5723-01
Jul 18, 2028
DobumaxDobutamine (as Hydrochloride)
50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
HLM Pharmaceutical Inc.Importer: H & B Pharma International Inc.
DRP-5723-11
Jul 18, 2028
DobumaxDobutamine (as hydrochloride)
50 mg/mL Solution for Intravenous InfusionIn a box of 1-Type I Amber Ampoule x 5 mL (Box of 5's)
Rx
Troikaa Pharmaceuticals Ltd.India
HLM Pharmaceutical Inc.Importer: Troikaa Pharmaceuticals Philippines, Inc.
DRP-10264-02
Oct 31, 2030
DobumeanDobutamine (as hydrochloride)
12.5 mg/mL (250 mg/20 mL) Solution for IV InfusionUSP Type I Clear Colorless Glass Vial x 20 mL (Box of 1's)
Rx
UNIJULES LIFE SCIENCES LIMITEDIndia
AGLOBAL CARE, INC.
DRP-7713
Nov 2, 2028
DobumedDobutamine (as hydrochloride)
50 mg/mL Solution for Injection (IV)USP Type I Amber glass ampoule x 5 mL (Box of 10's)
Rx
Makcur Laboratories LimitedIndia
Medwise, Inc.Importer: Hillcross Prime Inc.
DRP-11965-01
May 24, 2027
DobuminDobutamine (as hydrochloride)
50 mg/mL Solution for I.V. Infusion5 mL Type I Amber Glass Ampoule with Blue Dot; 10 ampoules in a tray, each tray in a box
Rx
Kwality Pharmaceuticals Pvt. Ltd.India
Pharma-Surrey International, Inc.
DRP-6706
Mar 24, 2031
DobumineDobutamine (as Hydrochloride)
50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Mehl Pharmaceutical TradingImporter: H & B Pharma International Inc.
DRP-5723-02
Jul 18, 2028
DobunexDobutamine (as hydrochloride)
50 mg/mL (250 mg/5 mL) Solution for IV InfusionUSP Type I Amber Glass Ampoule x 5 mL (Box of 5's)
Rx
Swiss Parenterals Ltd.India
Endure Medical, Inc.
DR-XY38330
Aug 4, 2028
DobuproDobutamine (as hydrochloride)
50 mg/mL Solution for Intravenous InfusionUSP Type I glass ampoule x 5 mL in PVC Tray (Box of 5’s)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Amediqo Phils., Inc.Importer: JLT Pharma Inc.
DRP-9050-03
Sep 19, 2031
DoburelDobutamine (as hydrochloride)
50 mg/mL (250 mg / 5 mL) Solution for Injection for I.V. InfusionUSP Type I amber coloured glass ampoule x 5 mL (Box of 5's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Epione Lifecare Inc.Importer: Despina Pharma Inc.
DRP-13429-02
Feb 16, 2028
DoburifemDobutamine (as hydrochloride)
50 mg / mL Solution for Injection (IV)USP Type I amber glass ampoule x 5 mL (Box of 5's)
Rx
Cooper Pharma LimitedIndia
Rifemedica CorporationImporter: Ambica International Corporation
DRP-11963-01
May 24, 2027
DoburifemDobutamine (as hydrochloride)
50 mg/mL Solution for IV InfusionUSP Type I Amber Glass Ampoule x 5 mL (Box of 5 ampoules)
Rx
Makcur Laboratories LimitedIndia
Rifemedica CorporationImporter: Diafarm Inc.
DRP-13326-01
Jan 27, 2028
DoburisDobutamine (as hydrochloride)
50 mg/mL Solution for Intravenous InfusionIn a box of 1-Type I Amber Ampoule x 5 mL Box of 5's
Rx
Troikaa Pharmaceuticals Ltd.India
Troikaa Pharmaceuticals Philippines, Inc.
DRP-10264
Oct 31, 2030
DoburxDobutamine (As Hydrochloride)
50 mg/mL Solution for IV InfusionType I Clear Glass Ampoule x 5 mL (Box of 5's)
Rx
Farbe FirmaIndia
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-12541
Aug 30, 2027
DobusanDobutamine (as hydrochloride)
50 mg/mL Solution for Injection (IV)USP Type I Amber glass ampoule x 5 mL (Box of 10's)
Rx
Makcur Laboratories LimitedIndia
Sanimed Pharmaceuticals Inc.Importer: Hillcross Prime Inc.
DRP-11965-02
May 24, 2027
DobusenzDobutamine (as Hydrochloride)
50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Starpharm, Inc.Importer: H & B Pharma International Inc.
DRP-5723-05
Jul 18, 2028
DobutafresDobutamine (as hydrochloride)
50 mg/mL Solution for IV InfusionType I amber glass ampoule x 5 mL (Box of 10 vials)
Rx
PT. Ethica Industri Farmasi (PT. Ethica)Indonesia
Fresenius Kabi Philippines Inc.
DR-XY48559
Jan 6, 2028
DOBUTAMDobutamine (as hydrochloride)
12.5 mg/mL (250 mg/20 mL) Solution for IV InfusionUSP Type I Clear Colorless Glass Vial x 20 mL (Box of 1's)
Rx
UNIJULES LIFE SCIENCES LIMITEDIndia
TRIPLE TACT IMPORT & EXPORT CORP.Importer: AGLOBAL CARE, INC.
DRP-7713-02
Nov 12, 2028
DobutasaphDobutamine
12.50mg/mL(250mg/20mL) Solution for Injection (IV Infusion)Type I Flint Clear Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap x 20 mL (Box of 1's)
Rx
Kilitch Drugs (India) Ltd.India
Ollen Pharma Trading, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11550
Mar 30, 2027
DOBUTAXDobutamine (as hydrochloride)
12.5 mg/mL (250 mg/20 mL) Solution for IV InfusionUSP Type I Clear Colorless Glass Vial x 20 mL (Box of 1's)
Rx
UNIJULES LIFE SCIENCES LIMITEDIndia
BELLUS LIFE SOLUTIONS, INC.Importer: AGLOBAL CARE, INC.
DRP-7713-04
Nov 12, 2028
DobutelDobutamine Hydrochloride
50 mg/mL (250 mg/5 mL) Solution for IV Injection5 mL (Net content) in 6 mL Type I Clear Glass Vial (Box of 1's)
Rx
PT. Novell Pharmaceutical LaboratoriesIndonesia
Prosweal Healthcare Inc.
DR-XY43206
Feb 13, 2029
DobutineDobutamine (as hydrochloride)
50 mg/mL (250 mg/ 5 mL) Solution for Injection for I.V. InfusionUSP Type I amber coloured glass ampoule x 5 mL (Box of 5’s)
Rx
Swiss Parenterals Ltd. (Block B)India
Epione Lifecare Inc.Importer: Despina Pharma Inc.
DRP-13429-01
Feb 16, 2028
DobutrimDobutamine (as hydrochloride)
25 mg / mL (250 mg / 10 mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule x 10 mL (Box of 10's)
Rx
Ciron Drugs & Pharmaceuticals Pvt., Ltd.India
International Apex Pharmaceutical, Inc.Importer: Phil Pharmawealth Inc.
DRP-3176-01
Oct 5, 2029
DOBUTSDobutamine (as hydrochloride)
12.5 mg/mL (250 mg/20 mL) Solution for IV InfusionUSP Type I Clear Colorless Glass Vial x 20 mL (Box of 1's)
Rx
UNIJULES LIFE SCIENCES LIMITEDIndia
APPLIED PHARMACEUTICAL DISTRIBUTION INCImporter: AGLOBAL CARE, INC.
DRP-7713-01
Nov 12, 2028
DobuventDobutamine
50 mg/mL Solution for I.V. Infusion5 mL Type I Amber Glass Ampoule with Blue Dot (10 ampoules in a tray, each tray in a box)
Rx
Kwality Pharmaceuticals Ltd.India
Seapharma International, Inc.Importer: Pharma-Surrey International, Inc
DRP-6706-01
May 24, 2031
DobuzefDobutamine (as Hydrochloride)
50 mg/mL (250 mg/ 5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Metro Pharma Philippines Inc.Importer: H & B Pharma International Inc.
DRP-5723-13
Jul 18, 2028
DobuzinDobutamine (as hydrochloride)
12.5 mg/mL (250 mg/20 mL) Solution for IV InfusionUSP Type I Clear Colorless Glass Vial x 20 mL (Box of 1's)
Rx
UNIJULES LIFE SCIENCES LIMITEDIndia
GREENCORE PHARMA INC.Importer: AGLOBAL CARE, INC.
DRP-7713-03
Nov 12, 2028
DociDobutamine (as hydrochloride)
12.50 mg/mL (250 mg/20 mL) Solution for Injection (IV Infusion)Type I Flint Clear Glass Vial Sealed with Bromobutyl Rubber Stopper And Aluminum Flip-Off Seal Cap x 20 mL (Box of 1’s)
Rx
Kilitch Drugs (India) Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ollen Pharma Trading Inc.Trader: Sapphire Lifesiences Pvt. Ltd.
DRP-11550-01
Mar 30, 2027
DotamineDobutamine (as hydrochloride)
50 mg/mL Solution for Intravenous InfusionUSP Type I glass ampoule x 5 mL in PVC Tray (Box of 5’s)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Bell-Kenz Pharma Inc.Importer: JLT Pharma Inc.
DRP-9050
Oct 31, 2030
GavaminDobutamine (as Hydrochloride)
50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Corbridge Group Phils., Inc.Importer: H & B Pharma International Inc.
DRP-5723-06
Jul 18, 2028
ImatimDobutamine (as Hydrochloride)
250 mg Lyophilized Powder for Injection (I.V.)USP Type I Flint Tubular Glass Vial x 20 mL (Box of 1's)
Rx
Gufic Biosciences Ltd.India
SRS Life Sciences Inc.
DR-XY40576
Jan 27, 2027
NoneDobutamine (as hydrochloride)
12.5 mg/mL (250 mg/20 mL) Solution for Injection for I.V. InfusionUSP Type I clear glass vial with 20 mm chlorobutyl rubber stopper and 20 mm flip off seal x 20 mL (Box of 1’s)
Rx
Concept Pharmaceuticals Ltd.India
Medethix, Inc.
DRP-18471
Jul 20, 2031
NoneDobutamine (as Hydrochloride)
12.5 mg/mL Solution for Injection (IV)Clear Glass Vial x 20mL with Rubber Stopper and Grey Flip-off Seal Box of 1’s
Rx
Hospira, Inc.USA
Importer: Pfizer, Inc.
DR-XY23120
Jul 21, 2027
NoneDobutamine (as hydrochloride)
50 mg/mL Solution for IV InfusionUSP Type I Amber Glass Ampoule x 5 mL (Box of 5 ampoules)
Rx
Makcur Laboratories LimitedIndia
Reta DrugImporter: Diafarm Inc.
DRP-13326-02
Jan 27, 2028
PredobutDobutamin (as Hydrochloride)Variant spelling
50mg/mL Solution for IV InfusionUSP Type I amber glass ampoule x 5 mL (Box of 5 ampoules)
Rx
Makcur Laboratories LimitedIndia
Diafarm Inc.
DRP-13326
Jan 27, 2028
PusogardDobutamine (as hydrochloride)
50 mg/mL (250 mg/mL) Solution for I.V. Injection5 mL Type I clear and colorless glass ampoule in PVC Tray (Box of 5's)
Rx
PT FERRON PAR PHARMACEUTICALSIndonesia
Glorious Dexa Mandaya, Inc.Trader: PT DEXA MEDICA
DRP-8132
Apr 28, 2029
RatamineDobutamine (as hydrochloride)
12.5 mg/mL Solution For Injection (IV Infusion)5 mL-Capacity Type 1 Amber Glass Ampoule x 3mL (Net content) (Box of 10's)
Rx
Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China
Raquel Abbas Pharma Inc.
DRP-19039
Oct 21, 2031
RetabuminDobutamine (as hydrochloride)
50mg/mL Solution for Intravenous (I.V.) Infusion5 mL USP Type I Amber Glass Ampoule x 5's in plastic tray (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
Reta DrugImporter: Afree Pharmaceutical Distribution Corp.
DRP-11918-03
May 20, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS 1. Increase in Heart Rate or Blood Pressure Dobutamine hydrochloride may cause a marked increase in heart rate or blood pressure, especially systolic pressure. Approximately 10% of patients in clinical studies have had rate increases of 30 beats/minute or more, and about 7.5% have had a 50 mm Hg or greater increase in systolic pressure.

Usually, reduction of dosage promptly reverses these effects. Because dobutamine hydrochloride facilitates atrioventricular conduction, patients with atrial fibrillation are at risk of developing rapid ventricular response. Patients with pre-existing hypertension appear to face an increased risk of developing an exaggerated pressor response. 2.

Ectopic Activity Dobutamine hydrochloride may precipitate or exacerbate ventricular ectopic activity, but it rarely has caused ventricular tachycardia. 3. Hypersensitivity Reactions suggestive of hyper-sensitivity associated with administration of Dobutamine Injection, USP, including skin rash, fever, eosinophilia, and bronchospasm, have been reported occasionally. 4.

Dobutamine Injection, USP contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.

Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions – Animal studies indicate that dobutamine may be ineffective if the patient has recently received a β-blocking drug. In such a case, the peripheral vascular resistance may increase. Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.

There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Increased Heart Rate, Blood Pressure, and Ventricular Ectopic Activity − A 10 to 20 mm increase in systolic blood pressure and an increase in heart rate of 5 to 15 beats/minute have been noted in most patients (see WARNINGS regarding exaggerated chronotropic and pressor effects). Approximately 5% of patients have had increased premature ventricular beats during infusions.

These effects are dose related. Hypotension − Precipitous decreases in blood pressure have occasionally been described in association with dobutamine therapy. Decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to baseline values. In rare cases, however, intervention may be required and reversibility may not be immediate.

Reactions at Sites of Intravenous Infusion − Phlebitis has occasionally been reported. Local inflammatory changes have been described following inadvertent infiltration. Isolated cases of cutaneous necrosis (destruction of skin tissue) have been reported. Miscellaneous Uncommon Effects − The following adverse effects have been reported in 1% to 3% of patients: nausea, headache, anginal pain, nonspecific chest pain, palpitations, and shortness of breath.

Isolated cases of thrombocytopenia have been reported. Administration of dobutamine hydrochloride, like other catecholamines, can produce a mild reduction in serum potassium concentration, rarely to hypokalemic levels (see PRECAUTIONS). Longer-Term Safety − Infusions of up to 72 hours have revealed no adverse effects other than those seen with shorter infusions.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy – Teratogenic Effects − Reproduction studies performed in rats at doses up to the normal human dose (10 mcg/kg/min for 24 h, total daily dose of 14.4 mg/kg), and in rabbits at doses up to twice the normal human dose, have revealed no evidence of harm to the fetus due to dobutamine hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers – It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when dobutamine hydrochloride is administered to a nursing woman. If a mother requires dobutamine hydrochloride treatment, breastfeeding should be discontinued for the duration of treatment.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The plasma half-life of dobutamine hydrochloride in humans is 2 minutes.

In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the β receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not cause the release of endogenous norepinephrine, as does dopamine.

In animal studies, dobutamine hydrochloride produces less increase in heart rate and less decrease in peripheral vascular resistance for a given inotropic effect than does isoproterenol. In patients with depressed cardiac function, both dobutamine hydrochloride and isoproterenol increase the cardiac output to a similar degree.

In the case of dobutamine hydrochloride, this increase is usually not accompanied by marked increases in heart rate (although tachycardia is occasionally observed), and the cardiac stroke volume is usually increased. In contrast, isoproterenol increases the cardiac index primarily by increasing the heart rate while stroke volume changes little or declines.

Facilitation of atrioventricular conduction has been observed in human electrophysiologic studies and in patients with atrial fibrillation. Systemic vascular resistance is usually decreased with administration of dobutamine hydrochloride. Occasionally, minimum vasoconstriction has been observed. Most clinical experience with dobutamine hydrochloride is short-term − not more than several hours in duration.

In the limited number of patients who were studied for 24, 48, and 72 hours, a persistent increase in cardiac output occurred in some, whereas output returned toward baseline values in others. The onset of action of dobutamine is within 1 to 2 minutes; however, as much as 10 minutes may be required to obtain the peak effect of a particular infusion rate.

The plasma half-life of dobutamine hydrochloride in humans is 2 minutes. The principal routes of metabolism are methylation of the catechol and conjugation. In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine. The 3-O-methyl derivative of dobutamine is inactive. Alteration of synaptic concentrations of catecholamines with either reserpine or tricyclic antidepressants does not alter the actions of dobutamine in animals, which indicates that the actions of dobutamine hydrochloride are not dependent on presynaptic mechanisms.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Dobutamine 50 mg/mL, 5 mL Ampule₱69.88–₱390.00Reference ₱145.85per ampuleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Dobutamine
PNF listingInj.: 50 mg/mL, 5 mL ampul (concentrate) (IV infusion) (as hydrochloride)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PNF listingInj.: 2 mg/mL, 250 mL D5W (pre-mixed) (IV) (as hydrochloride)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. DOBUTAMINE · Hospira, Inc. [US FDA-approved label, version 19, May 27, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89becb0c-da60-4f43-0a98-29ff7a9eca58
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .